Shattuck Labs Finalizes $75M Public Offering at $4.00/Share, Significant Dilution Expected

summarizeSummary

Shattuck Labs has formalized a public offering of common stock and pre-funded warrants, raising up to $81.1 million at $4.00 per share, which will significantly dilute existing shareholders but provides essential capital for clinical development.

check_boxKey Events

• Public Offering Finalized

  Shattuck Labs is selling 10,879,376 shares of common stock and pre-funded warrants to purchase 7,870,624 shares, totaling 18,750,000 shares. This finalizes the terms of an offering previously reported as priced on June 10, 2026.

• Pricing Details

  The offering price is $4.00 per share of common stock and $3.9999 per pre-funded warrant. This is at a discount to the last reported sale price of $4.27 on June 9, 2026.

• Capital Raised

  The company expects to receive net proceeds of approximately $70.5 million, potentially increasing to $81.1 million if the underwriters fully exercise their option to purchase an additional 2,812,500 shares.

• Significant Dilution

  The offering could result in a dilution of 24.8% to 28.5% of existing shares outstanding, based on 75.6 million shares outstanding as of March 31, 2026.

auto_awesomeAnalysis

This 424B5 prospectus supplement formalizes the terms of a public offering, previously reported as priced on June 10, 2026, and finalized on June 11, 2026. The offering will raise approximately $70.5 million (or up to $81.1 million if the underwriters' option is fully exercised) through the sale of common stock and pre-funded warrants. The offering price of $4.00 per share is at a discount to the recent market price. This capital raise is highly dilutive, potentially increasing outstanding shares by 24.8% to 28.5%, but provides crucial funding for ongoing clinical trials and general corporate purposes, extending the company's cash runway.